obesity drugs

IPO scout look ahead telescope up forward

Lilly, Haya ink $1B biobuck obesity pact to search dark genome

Lilly has put together a deal worth up to $1 billion in biobucks to partner with Haya to find multiple regulatory-genome-derived RNA-based drug targets.

Nick Paul Taylor Sep 4, 2024 8:00am

Graphic image of the letters IPO in white in front of a yellow background

MBX files for IPO to take challenger to Ascendis into phase 3

Aug 26, 2024 9:40am

Arrowhead dips toes into obesity pond with 2 preclinical assets

Aug 14, 2024 3:50pm

weight loss scale weigh measure tape obesity overweight

Rivus’ phase 2 obesity-related heart failure trial hits endpoint

Aug 13, 2024 8:57am

arrow back backwards u-turn turn around reverse

Novo Nordisk axes once-monthly GLP-1/GIP agonist MASH prospect

Aug 7, 2024 7:00am

Viking to charge quickly into phase 3 with obesity med

Jul 25, 2024 9:19am